Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans cut its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 10.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 226,329 shares of the biotechnology company's stock after selling 27,754 shares during the quarter. Thrivent Financial for Lutherans owned 0.30% of Axon Enterprise worth $134,556,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its holdings in Axon Enterprise by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company's stock worth $710,103,000 after buying an additional 35,320 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in Axon Enterprise by 12.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company's stock worth $469,661,000 after buying an additional 127,769 shares in the last quarter. Champlain Investment Partners LLC lifted its holdings in Axon Enterprise by 13.9% during the 3rd quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company's stock worth $272,695,000 after buying an additional 83,265 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Axon Enterprise by 1.6% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company's stock worth $224,281,000 after buying an additional 9,090 shares in the last quarter. Finally, Groupama Asset Managment acquired a new stake in Axon Enterprise during the 3rd quarter worth approximately $200,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Activity

In other news, insider Jeffrey C. Kunins sold 1,035 shares of the company's stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $624.47, for a total value of $646,326.45. Following the completion of the sale, the insider now directly owns 124,243 shares of the company's stock, valued at approximately $77,586,026.21. This represents a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeri Williams sold 307 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $552.72, for a total transaction of $169,685.04. Following the transaction, the director now owns 1,627 shares in the company, valued at approximately $899,275.44. This trade represents a 15.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,792 shares of company stock valued at $1,087,843. Insiders own 5.70% of the company's stock.

Axon Enterprise Stock Performance

AXON traded up $1.59 on Friday, reaching $560.00. The company had a trading volume of 802,214 shares, compared to its average volume of 845,276. The stock has a 50-day moving average price of $591.90 and a 200-day moving average price of $540.96. Axon Enterprise, Inc. has a 1 year low of $273.52 and a 1 year high of $715.99. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $42.91 billion, a PE ratio of 144.70, a P/E/G ratio of 5.17 and a beta of 1.12.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on AXON shares. JMP Securities reaffirmed an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. TD Cowen started coverage on shares of Axon Enterprise in a research report on Wednesday, January 8th. They set a "buy" rating and a $700.00 price objective for the company. Barclays reaffirmed a "hold" rating on shares of Axon Enterprise in a research report on Monday, March 10th. The Goldman Sachs Group lifted their price objective on shares of Axon Enterprise from $500.00 to $700.00 and gave the stock a "buy" rating in a research report on Monday, January 27th. Finally, Morgan Stanley raised shares of Axon Enterprise from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $500.00 to $700.00 in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $604.67.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.